NCT06843811Enrolling By Invitation2 期
A Pilot Phase 2 Study with Long-Term Extension to Assess the Safety and Efficacy of Sirolimus in Patients with Leigh Syndrome Caused by Genetically-Confirmed Mitochondrial Respiratory Chain Deficiency
Matthew Demczko1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年2月27日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Rate of Adverse Events
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of the drug Sirolimus in participants with Leigh syndrome.
详细描述
This is a pilot phase 2 study with long-term extension to evaluate the safety and efficacy of enteral sirolimus in patients with genetically-confirmed Leigh syndrome.
Sirolimus will be given daily at a starting dose of 0.8 to 1.3 mg/m2 depending on subject age, weight, and BSA (body surface area). Dosage will be adjusted as needed based on sirolimus trough level to maintain patients within a range of 5 to10 ng/mL, a level lower than what is targeted in renal transplant recipients. Patients will be followed through this study for up to 24 weeks in the active phase. Participants who are eligible for the long-term extension may choose to stay on drug for up to 2 years thereafter
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Genetically-confirmed diagnosis of Leigh syndrome with neurodevelopmental manifestations, which include documented developmental delay, developmental regression, or abnormal neurologic exam findings including but not limited to hypotonia, hypertonia, dystonia, chorea, nystagmus, ataxia, dysmetria, tremor or muscle weakness.
- •Age 6 months to 55 years at the time of enrollment.
- •Weight ≥ 5 kg at the time of enrollment.
- •Adequate liver function as evidenced by total bilirubin < 1.5x upper limit of normal (ULN) and liver function tests, alanine transaminase (ALT) and aspartate aminotransferase (AST), < 3x ULN.
- •Adequate renal function as evidenced by glomerular filtration rate (GFR) > 60 mL/min/1.73m2 (cystatin C for pediatric population).
- •Normal hematologic parameters as defined as:
- •Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- •Platelet count ≥ 100,000/mm3 (100 x 109/L)
- •Hemoglobin ≥ 9 g/dL
- •Non-fasting serum triglycerides and cholesterol < 300 mg/dL.
- •Serum amylase and lipase < 2x ULN.
- •Adequate immunoglobulin levels as outlined below that, in the opinion of the investigator, will not place the patient at increased risk of infection.
- •Immunoglobulin G (IgG) ≥ 200 mg/dL
- •Immunoglobulin M (IgM) ≥ 30 mg/dL
- •Immunoglobulin A (IgA) ≥ 10 mg/dL
- •All sexually active participants must agree to use effective contraception:
- •Females of child-bearing potential must agree to use effective contraception without interruption from 28 days prior to starting Investigational Product (IP) throughout 3 months after last dose of IP and have a negative urine pregnancy test result at screening and agree to ongoing pregnancy testing during the course of the study.
- •Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after the last dose of investigational drug.
- •The patient or parent(s)/legal guardian(s) is/are willing and able to comply with the study visit schedule and other protocol requirements, in the opinion of the investigator.
- •The patient or the patient's parent(s)/legal guardian(s) understand(s) and voluntarily sign(s) the informed consent documents(s) prior to any study-related assessments/procedures being conducted.
排除标准
- •Cardiac ejection fraction ≤ 50 %, shortening fraction ≤ 25% on cardiac echocardiogram within one year of screening and/or severe end-organ hypo-perfusion syndrome (secondary to cardiac failure) resulting in lactic acidosis.
- •Patients with implanted cardiac assist/medical devices (including pacemakers), unless device was implanted prophylactically, and the patient is clinically asymptomatic.
- •In the opinion of the investigator, clinically significant ECG and/or echocardiogram alterations at the time of screening.
- •Myocardial infarction within 6 months prior to enrollment.
- •Symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, or unstable coronary artery disease.
- •Prior history of hypersensitivity to sirolimus or other mTOR (Mechanistic Target of Rapamycin inhibitors).
- •Prior history of angioedema requiring treatment or cessation of a presumed causative agent.
- •Planned surgical procedure during the study period.
- •Confirmed or highly suspected immunodeficiency disorder(s), including but not limited to, common variable immune deficiency (CVID), complement deficiency, etc.
- •Clinically significant proteinuria that requires ongoing medical therapy.
- •Any uncontrolled psychiatric or medical condition which, in the opinion of the investigator, would interfere with the patient's participation in the study.
- •Patients who are breastfeeding or are pregnant.
- •History of solid organ transplant (kidney, liver, heart, lung) or bone marrow transplant.
- •Treatment with any investigational drug (i.e., a drug for which there is no approved indication), including an investigational drug for mitochondrial disease within 1 month prior to receiving the first dose of study drug (or within 3 months for a trial with an investigational biologic).
- •Patients with confirmed or suspected increased intracranial pressure, pseudotumor cerebri (PTC)/idiopathic intracranial hypertension, and or papilledema.
- •Currently active malignancy (other than adequately treated non-melanoma skin cancers [i.e., squamous cell and/or basal cell carcinoma], carcinoma in situ of the cervix, or other adequately treated carcinoma in situ) and/or ongoing treatment for malignancy are ineligible. Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for ≥ 1 year.
- •Recent infection requiring systemic anti-infective treatment that was completed ≤ 14 days prior to enrollment.
- •Uncontrolled diabetes mellitus, as defined by HbA1c > 8%, despite adequate therapy.
- •History of interstitial lung disease and/or pneumonitis.
- •Use of strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) and/or p-glycoprotein (p-GP) within the 14 days prior to receiving the first dose of study drug. Additionally, use of any known CYP3A4 substrates with a narrow therapeutic window (e.g., fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfenadine) within the 14 days prior to receiving the first dose of study drug.
- •Use of medications with a high risk of angioedema
- •Known human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infection(s).
研究组 & 干预措施
Phase 2A
Experimental
Participants will receive Sirolimus for at least 24 weeks at a starting dose of 0.8 to 1.3 mg/m2 two (2) times daily.
干预措施: Sirolimus (Drug)
Long-Term Extension
Experimental
Eligible participants may continue Sirolimus treatment for up to two (2) years.
干预措施: Sirolimus (Drug)
结局指标
主要结局
Rate of Adverse Events
时间窗: Up to 2.5 years
Adverse events will be measured according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Incidence of AEs will be reported.
Rate of Intercurrent Infection and Hospitalization
时间窗: Up to 2.5 years
Each infection and hospitalization will be reported.
Incidence of abnormal safety lab values
时间窗: Up to 2.5 years
Count of clinically significant changes from baseline in safety labs
Sirolimus Trough Level
时间窗: Up to 2.5 years
Measure of Sirolimus level in the blood. Sirolimus dosage will be adjusted as needed in order to maintain a sirolimus trough level within a range of 5 to 10 ng/mL. The number of out-of-range results will be reported.
次要结局
- Change in MM-COAST Score(Baseline up to end of study (up to 2.5 years))
- Change in GMFM (Gross Motor Function Measure) Score(Baseline up to end of study (up to 2.5 years))
- Change in Movement Disorder-Childhood Rating Score (MDCRS)(Baseline up to end of study (up to 2.5 years))
- CGI Scale(Baseline up to end of study (up to 2.5 years))
- Change in Barry-Albright Dystonia Scale (BADS)(Baseline up to end of study (up to 2.5 years))
- Change in Scale for the Assessment and Rating of Ataxia (SARA)(Baseline up to end of study (up to 2.5 years))
- Newcastle Pediatric Mitochondrial Disease Scale (NPMDS)(Baseline up to end of study (up to 2.5 years))
- Newcastle Adult Mitochondrial Disease Scale (NMDAS)(Baseline up to end of study (up to 2.5 years))
- Change in PEDI-CAT Score(Baseline up to end of study (up to 2.5 years))
- Patient Global Impression of Change (PGIC)(Baseline up to end of study (up to 2.5 years))
- Change in PedsQL(Baseline up to end of study (up to 2.5 years))
- Change in MFIS(Baseline up to end of study (up to 2.5 years))
- Change in Karnofsky-Lansky(Baseline up to end of study (up to 2.5 years))
研究者
Matthew Demczko
Sponsor-Investigator
Children's Hospital of Philadelphia
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Pilot-Study of Sirolimus for the Treatment of Systemic SclerosisSystemic SclerosisNCT03365869Peking University People's Hospital72
终止
1 期
Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorMultiple Sclerosis (MS) - Relapsing-remittingNCT00095329National Institute of Allergy and Infectious Diseases (NIAID)14
已完成
2 期
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior TreatmentGraft Versus Host DiseaseNCT00079183Fred Hutchinson Cancer Center44
终止
2 期
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis ComplexAngiofibroma of FaceTuberous SclerosisNCT03363763Aucta Pharmaceuticals, Inc24
已完成
2 期
Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesKaposiform HemangioendotheliomasTufted AngiomaCapillary Venous Lymphatic MalformationVenous Lymphatic MalformationMicrocystic Lymphatic MalformationMucocutaneous Lymphangiomatosis and ThrombocytopeniaCapillary Lymphatic Arterial Venous MalformationsPTEN Overgrowth Syndrome With Vascular AnomalyLymphangiectasia SyndromesNCT00975819Denise Martin Adams61